Approval Year
| Substance Class |
Structurally Diverse
Created
by
admin
on
Edited
Mon Mar 31 20:10:33 GMT 2025
by
admin
on
Mon Mar 31 20:10:33 GMT 2025
|
| Source Materials Class | ORGANISM |
| Source Materials Type | VIRUS |
| Organism Family | Herpesviridae |
| Organism Genus | Simplexvirus |
| Organism Species | human herpesvirus 2 |
| Author | NONE |
| Part | whole |
| Record UNII |
74J6DNH49U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
74J6DNH49U
Created by
admin on Mon Mar 31 20:10:33 GMT 2025 , Edited by admin on Mon Mar 31 20:10:33 GMT 2025
|
PRIMARY | |||
|
74J6DNH49U
Created by
admin on Mon Mar 31 20:10:33 GMT 2025 , Edited by admin on Mon Mar 31 20:10:33 GMT 2025
|
PRIMARY | |||
|
1318479
Created by
admin on Mon Mar 31 20:10:33 GMT 2025 , Edited by admin on Mon Mar 31 20:10:33 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
|
INHIBITOR->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
IC50
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
The 9-(3,4-dihydroxybut-1-yl)guanine (bucyclovir, 23) with a hydroxyl directly attached to the butyl side chain is very potent against HSV-1 and HSV-2 (IC50=0.4 ?M against HSV-1 and 0.9 ?M against HSV-2). The stereochemistry of the 3-position of bucyclovir is crucial in determining the antiherpetic activities. While the R configuration is very potent, the S-isomer (24) is essentially inactive against HSV-1 and HSV-2.
IC50
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
The in vitro activities of penciclovir against HSV-1, HSV-2 and VZV are similar to those of aciclovir, with median IC50 values of 0.4, 1.5 and 4.0?µg/mL, respectively, in MRC-5 cells.
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
